HALO logo

Halozyme Therapeutics (HALO) Cash from investing

annual CFI:

-$262.72M-$165.81M(-171.10%)
December 31, 2024

Summary

  • As of today (June 22, 2025), HALO annual cash flow from investing activities is -$262.72 million, with the most recent change of -$165.81 million (-171.10%) on December 31, 2024.
  • During the last 3 years, HALO annual CFI has risen by +$143.57 million (+35.34%).
  • HALO annual CFI is now -435.30% below its all-time high of $78.35 million, reached on December 31, 2020.

Performance

HALO Cash from investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherHALOcash flow metrics

quarterly CFI:

-$90.42M-$119.90M(-406.72%)
March 31, 2025

Summary

  • As of today (June 22, 2025), HALO quarterly cash flow from investing activities is -$90.42 million, with the most recent change of -$119.90 million (-406.72%) on March 31, 2025.
  • Over the past year, HALO quarterly CFI has dropped by -$7.74 million (-9.36%).
  • HALO quarterly CFI is now -254.72% below its all-time high of $58.44 million, reached on December 31, 2020.

Performance

HALO quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherHALOcash flow metrics

TTM CFI:

-$270.46M-$7.74M(-2.95%)
March 31, 2025

Summary

  • As of today (June 22, 2025), HALO TTM cash flow from investing activities is -$270.46 million, with the most recent change of -$7.74 million (-2.95%) on March 31, 2025.
  • Over the past year, HALO TTM CFI has dropped by -$151.04 million (-126.47%).
  • HALO TTM CFI is now -311.17% below its all-time high of $128.08 million, reached on September 30, 2019.

Performance

HALO TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherHALOcash flow metrics

Cash from investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

HALO Cash from investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-171.1%-9.4%-126.5%
3 y3 years+35.3%-83.4%+34.1%
5 y5 years-4634.6%-337.3%-7318.1%

HALO Cash from investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-171.1%+46.0%-264.4%+79.2%-3314.1%+66.2%
5 y5-year-435.3%+46.0%-254.7%+79.2%-445.2%+66.2%
alltimeall time-435.3%+46.0%-254.7%+79.2%-311.2%+66.2%

HALO Cash from investing History

DateAnnualQuarterlyTTM
Mar 2025
-
-$90.42M(-406.7%)
-$270.46M(+2.9%)
Dec 2024
-$262.72M(+171.1%)
$29.48M(-117.6%)
-$262.72M(-12.6%)
Sep 2024
-
-$167.48M(+298.4%)
-$300.49M(+38.8%)
Jun 2024
-
-$42.04M(-49.2%)
-$216.46M(+81.2%)
Mar 2024
-
-$82.68M(+897.2%)
-$119.43M(+23.2%)
Dec 2023
-$96.91M(-80.1%)
-$8.29M(-90.1%)
-$96.91M(+7.2%)
Sep 2023
-
-$83.45M(-251.7%)
-$90.36M(+1040.7%)
Jun 2023
-
$54.99M(-191.4%)
-$7.92M(-98.4%)
Mar 2023
-
-$60.16M(+3345.7%)
-$497.86M(+2.2%)
Dec 2022
-$487.00M(+19.9%)
-$1.75M(+73.2%)
-$487.00M(-37.9%)
Sep 2022
-
-$1.01M(-99.8%)
-$784.73M(-2.0%)
Jun 2022
-
-$434.95M(+782.2%)
-$800.67M(+95.1%)
Mar 2022
-
-$49.30M(-83.5%)
-$410.34M(+1.0%)
Dec 2021
-$406.29M(-618.5%)
-$299.47M(+1666.4%)
-$406.29M(+739.8%)
Sep 2021
-
-$16.95M(-62.0%)
-$48.38M(-21.4%)
Jun 2021
-
-$44.62M(-1.4%)
-$61.52M(+1129.2%)
Mar 2021
-
-$45.25M(-177.4%)
-$5.00M(-106.4%)
Dec 2020
$78.35M(-1512.0%)
$58.44M(-294.2%)
$78.35M(-176.1%)
Sep 2020
-
-$30.09M(-352.9%)
-$102.91M(+223.5%)
Jun 2020
-
$11.90M(-68.8%)
-$31.81M(-949.0%)
Mar 2020
-
$38.11M(-131.0%)
$3.75M(-167.5%)
Dec 2019
-$5.55M(-322.6%)
-$122.82M(-399.6%)
-$5.55M(-104.3%)
Sep 2019
-
$41.00M(-13.6%)
$128.08M(+4.8%)
Jun 2019
-
$47.46M(+64.7%)
$122.27M(+81.9%)
Mar 2019
-
$28.81M(+166.6%)
$67.21M(+2595.8%)
Dec 2018
$2.49M(-101.5%)
$10.81M(-69.3%)
$2.49M(-101.6%)
Sep 2018
-
$35.19M(-562.6%)
-$157.30M(-3.0%)
Jun 2018
-
-$7.61M(-78.8%)
-$162.21M(-20.4%)
Mar 2018
-
-$35.90M(-75.9%)
-$203.90M(+24.5%)
Dec 2017
-$163.73M(+113.3%)
-$148.99M(-592.0%)
-$163.73M(-2698.5%)
Sep 2017
-
$30.28M(-161.4%)
$6.30M(-140.0%)
Jun 2017
-
-$49.29M(-1255.7%)
-$15.74M(-147.5%)
Mar 2017
-
$4.26M(-79.7%)
$33.12M(-143.1%)
Dec 2016
-$76.77M(-1403.8%)
$21.05M(+155.2%)
-$76.77M(-31.8%)
Sep 2016
-
$8.25M(-1995.6%)
-$112.57M(+12.0%)
Jun 2016
-
-$435.00K(-99.6%)
-$100.52M(+12.5%)
Mar 2016
-
-$105.62M(+615.8%)
-$89.31M(-1616.9%)
Dec 2015
$5.89M(-117.9%)
-$14.76M(-172.7%)
$5.89M(-82.7%)
Sep 2015
-
$20.29M(+88.4%)
$34.13M(+107.3%)
Jun 2015
-
$10.77M(-203.4%)
$16.46M(-9245.0%)
Mar 2015
-
-$10.42M(-177.3%)
-$180.00K(-99.5%)
Dec 2014
-$32.95M(-31.2%)
$13.48M(+413.0%)
-$32.95M(-25.8%)
Sep 2014
-
$2.63M(-144.8%)
-$44.42M(-6.2%)
Jun 2014
-
-$5.87M(-86.4%)
-$47.37M(+13.9%)
Mar 2014
-
-$43.19M(-2241.3%)
-$41.58M(-13.1%)
Dec 2013
-$47.87M
$2.02M(-720.6%)
-$47.87M(-5.1%)
Sep 2013
-
-$325.00K(+306.3%)
-$50.43M(+0.3%)
DateAnnualQuarterlyTTM
Jun 2013
-
-$80.00K(-99.8%)
-$50.27M(-1.3%)
Mar 2013
-
-$49.48M(+9066.5%)
-$50.91M(+3503.0%)
Dec 2012
-$1.41M(+70.5%)
-$539.80K(+222.3%)
-$1.41M(-1.2%)
Sep 2012
-
-$167.50K(-76.8%)
-$1.43M(+9.9%)
Jun 2012
-
-$721.50K(-4666.5%)
-$1.30M(+113.5%)
Mar 2012
-
$15.80K(-102.8%)
-$609.70K(-26.4%)
Dec 2011
-$828.50K(+28.2%)
-$557.00K(+1328.2%)
-$828.50K(+37.6%)
Sep 2011
-
-$39.00K(+32.2%)
-$602.20K(-3.5%)
Jun 2011
-
-$29.50K(-85.5%)
-$623.80K(-10.9%)
Mar 2011
-
-$203.00K(-38.6%)
-$700.40K(+8.4%)
Dec 2010
-$646.50K(-55.7%)
-$330.70K(+445.7%)
-$646.40K(-26.5%)
Sep 2010
-
-$60.60K(-42.9%)
-$879.10K(-9.3%)
Jun 2010
-
-$106.10K(-28.8%)
-$969.40K(-24.9%)
Mar 2010
-
-$149.00K(-73.6%)
-$1.29M(-11.6%)
Dec 2009
-$1.46M(+26.0%)
-$563.40K(+273.4%)
-$1.46M(+27.0%)
Sep 2009
-
-$150.90K(-64.7%)
-$1.15M(-19.8%)
Jun 2009
-
-$427.80K(+34.1%)
-$1.43M(+12.6%)
Mar 2009
-
-$319.00K(+26.4%)
-$1.27M(+9.8%)
Dec 2008
-$1.16M(-51.0%)
-$252.40K(-42.0%)
-$1.16M(-40.2%)
Sep 2008
-
-$435.40K(+63.1%)
-$1.94M(-0.1%)
Jun 2008
-
-$267.00K(+30.2%)
-$1.94M(-19.4%)
Mar 2008
-
-$205.00K(-80.2%)
-$2.41M(+1.9%)
Dec 2007
-$2.37M(+548.4%)
-$1.03M(+136.6%)
-$2.37M(+64.1%)
Sep 2007
-
-$436.70K(-40.5%)
-$1.44M(+24.2%)
Jun 2007
-
-$734.50K(+356.5%)
-$1.16M(+138.5%)
Mar 2007
-
-$160.90K(+47.2%)
-$486.80K(+33.4%)
Dec 2006
-$364.80K(+4.0%)
-$109.30K(-30.0%)
-$364.80K(+38.8%)
Sep 2006
-
-$156.20K(+158.6%)
-$262.90K(+29.3%)
Jun 2006
-
-$60.40K(+55.3%)
-$203.40K(-21.5%)
Mar 2006
-
-$38.90K(+425.7%)
-$259.10K(-26.2%)
Dec 2005
-$350.90K(+53.9%)
-$7400.00(-92.3%)
-$350.90K(-23.6%)
Sep 2005
-
-$96.70K(-16.7%)
-$459.00K(+18.9%)
Jun 2005
-
-$116.10K(-11.2%)
-$386.20K(+22.0%)
Mar 2005
-
-$130.70K(+13.2%)
-$316.60K(+38.9%)
Dec 2004
-$228.00K(<-9900.0%)
-$115.50K(+383.3%)
-$227.90K(+328.4%)
Sep 2004
-
-$23.90K(-48.6%)
-$53.20K(+21.2%)
Jun 2004
-
-$46.50K(+10.7%)
-$43.90K(+4.5%)
Mar 2004
-
-$42.00K(-170.9%)
-$42.00K(<-9900.0%)
Dec 2003
$0.00(0.0%)
$59.20K(-505.5%)
$0.00(-100.0%)
Sep 2003
-
-$14.60K(-67.3%)
-$34.20K(+74.5%)
Jun 2003
-
-$44.60K(<-9900.0%)
-$19.60K(<-9900.0%)
Mar 2003
-
$0.00(-100.0%)
$0.00(0.0%)
Dec 2002
$0.00(0.0%)
$25.00K(>+9900.0%)
$0.00(-100.0%)
Sep 2002
-
$0.00(-100.0%)
-$25.00K(0.0%)
Jun 2002
-
-$25.00K(<-9900.0%)
-$25.00K(<-9900.0%)
Mar 2002
-
$0.00
$0.00
Dec 2001
$0.00
-
-

FAQ

  • What is Halozyme Therapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual CFI year-on-year change?
  • What is Halozyme Therapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Halozyme Therapeutics?
  • What is Halozyme Therapeutics quarterly CFI year-on-year change?
  • What is Halozyme Therapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Halozyme Therapeutics?
  • What is Halozyme Therapeutics TTM CFI year-on-year change?

What is Halozyme Therapeutics annual cash flow from investing activities?

The current annual CFI of HALO is -$262.72M

What is the all time high annual CFI for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual cash flow from investing activities is $78.35M

What is Halozyme Therapeutics annual CFI year-on-year change?

Over the past year, HALO annual cash flow from investing activities has changed by -$165.81M (-171.10%)

What is Halozyme Therapeutics quarterly cash flow from investing activities?

The current quarterly CFI of HALO is -$90.42M

What is the all time high quarterly CFI for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly cash flow from investing activities is $58.44M

What is Halozyme Therapeutics quarterly CFI year-on-year change?

Over the past year, HALO quarterly cash flow from investing activities has changed by -$7.74M (-9.36%)

What is Halozyme Therapeutics TTM cash flow from investing activities?

The current TTM CFI of HALO is -$270.46M

What is the all time high TTM CFI for Halozyme Therapeutics?

Halozyme Therapeutics all-time high TTM cash flow from investing activities is $128.08M

What is Halozyme Therapeutics TTM CFI year-on-year change?

Over the past year, HALO TTM cash flow from investing activities has changed by -$151.04M (-126.47%)
On this page